Drug Profile
AGN 223575
Alternative Names: AGN-223575Latest Information Update: 18 May 2020
Price :
$50
*
At a glance
- Originator Allergan
- Class Eye disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Dry eyes
Most Recent Events
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 25 Oct 2018 Discontinued - Phase-II for Dry eyes in USA (Ophthalmic)
- 01 Jan 2016 Allergan completes a phase II trial in Dry eyes in USA (Ophthalmic) (NCT02435914)